Excited for another great myeloid workshop at ASH this year! Please send us your most exciting science!

Uli Steidl@steidluli.bsky.social · 2w ago

🔥🔥🔥 🐔🐔🐔 👇👇👇

Happy to contribute to this exciting project just published in @nature.com led by the amazing Shoichiro Takeishi in a fantastic collaboration with @steidluli.bsky.social - check out this thread 🩸 🧬

Uli Steidl@steidluli.bsky.social · 11mo ago

Please check out this thread on our latest paper in @nature.com on HSC pool size regulation. rdcu.be/eCJLe Phenomenal collaboration with @gritsmanlab.bsky.social, and driven by the outstanding Shoichiro Takeishi! @einsteincellbio.bsky.social @einsteinmededu.bsky.social (1/6)

Glimmer of hope: the Senate Labor, Health and Human Services Subcommittee just voted, 26 to 3, to reject the administration’s proposed cuts & instead recommend a $400 million increase to the NIH budget. The House LHHS Subcommittee convenes in September www.appropriations.senate.gov/news/minorit... 🧪

Senate Appropriations Committee Approves Defense and Labor, Health and Human Services, and Education Bills | United States Senate Committee on Appropriations

United States Senate Committee on Appropriations

appropriations.senate.gov

So impressed at the increased support the American Society of Hematology is planning for trainees and early-career investigators!! At some point, someone invested in us. Now it’s our turn. #Fight4Hematology and secure the future of hematology research. Donate! #hemesky www.hematology.org/foundation

Interested in a mentor to guide your career in malignant hematology? Apply for the ASH’s new Mentorship Program, and grow your network! Deadline: Sept 26. Apply today! 🔗 https://bit.ly/3IPWjMA Interested in becoming a mentor? Sign up today: https://bit.ly/3U5tm1t #HemeSky

The Myeloid Workshop is back in ASH! Please contact the organizers if you have an exciting story that will not be out by December they are: Zuzana Tothova , @ernstlaboratory.bsky.social @steidluli.bsky.social @ericpietras.bsky.social @kathrinbernt.bsky.social @gritsmanlab.bsky.social

Check out our new preprint on an epigenetic resistance mechanism to PI3 kinase inhibition in AML and a new combination therapy with an EZH1/2 inhibitor that depletes leukemic stem cells! Great effort by @thehematopoet and the whole team

Shira G-S, PhD@thehematopoet.bsky.social · last yr.

So excited to share a pre-print of my thesis work! Check it out to see how we can leverage an epigenetic resistance mechanism to PI3K inhibitors to target leukemic stem cells!! (Spoiler alert: PRC2 is involved!) Really proud of this work conducted with @gritsmanlab.bsky.social

So excited that our collaboration with the Shechter lab on a new targetable PTM -glutamylation- on NPM1c in AML is now on BioRxiv! Team effort led by @alexkschurer.bsky.social and @humaira2204.bsky.social! 🧪🩸

David Shechter@dshechter.bsky.social · last yr.

We discovered a new AML vulnerability: TTLL4 glutamylates NPM1c and helps leukemia cells thrive. Knock it down and cells differentiate and survival improves. Collab between our lab and @Gritsman_lab—funded by NIH and DoD/CDMRP. Preprint: bit.ly/42oZl09 /1

#NIHfunding cuts have resulted in stalled research. In response, ASH is expanding its Bridge Grant Program with $150K in awards to support critical research by members. Donate to support #hematology researchers and help ensure innovative research continues: https://bit.ly/41LFwjD #HemeSky #MedSky

If you have applied to an R01 or equivalent, please check out the new eligibility. #hematology #medsky #phdsky #scisky #science

American Society of Hematology@ash.hematology.org · last yr.

In response to changes in the #NIHfunding, ASH is expanding access and eligibility for the 2025 Bridge Grant Program for #researchers. Ready to enhance your career? Apply today: https://bit.ly/3F55fvz #ASHAwards #Hematology #Grants #Hemesky #Fight4Hematolog

I have been talking to the media, Time, Fortune, NBC, etc., to explain how the onslaught on science and NIH will impact the health of all Americans. Everyone knows someone who has cancer, heart disease, or depression. Spread the word about how cutting science impacts all. time.com/7216299/nih-...

Experts Call NIH Budget Cuts an 'Apocalypse' for Science

The reductions target indirect costs that cover administrative and equipment costs.

time.com

📢 Support federal research funding! As the new Administration acts & Congress finalizes FY25 funding, lawmakers need to hear from you. Share your stories of how funding & policies impact #hematology patients & research. Take action! bit.ly/4b2bj43 #Fight4Hematology #HemeSky #BloodSky

Calling all aspiring hematologists in med school — don’t leave research funding on the table! 💰 ✨ HIP Medical Student Award ✨ HONORS Award ✨ Physician-Scientist Award Learn more: https://bit.ly/4hexNk7. Your application is due on Feb. 14! #ASHTrainee #HemeSky #BloodSky #Hematology

Congratulations to all the new ASH Scholars!

American Society of Hematology@ash.hematology.org · 2y ago

#ASHKudos to the 2025 ASH Scholar Award recipients! This award supports early career investigators as they transition from training programs to careers as independent investigators. Learn more: https://bit.ly/4haW3Ue #ASHAwards #Hematology #HemeSky #BloodSky @b-avalos-md.bsky.social

Delighted to share our #hematology review article on mutant calreticulin in #MPN Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below! @stanforddeptmed.bsky.social link.springer.com/article/10.1...

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications - Current Hematologic Malignancy Reports

Purpose of Review More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continu...

link.springer.com

Inflammation plays a key role in RUNX1-FPD pathogenesis. Dr. Anupriya Agarwal & her team at @ohsunews.bsky.social found targeting CD74 signaling, mTOR & JAK1/2 pathways could prevent disease progression. Incredible work by an RRP-EdwardPEvansFdn FIRE grant recipient! www.science.org/doi/10.1126/...

Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder

CD74 signaling drives inflammation and differentiation defects in hematopoietic stem and progenitor cells in RUNX1-familial platelet disorder.

science.org

Stanford #Hematology is recruiting! #ASH24 attendees, pls reach out to me if interested! 👇🏽@stanforddeptmed.bsky.social

Ann Mullally@mullallylab.bsky.social · 2y ago

Stanford Hematology is recruiting a physician-scientist in heme malignancies, details below, pls share, pls reach out with Qs, I’m excited to grow our amazing Division! @stanforddeptmed.bsky.social

Excited for this workshop this afternoon and grateful to the organizers Christina Glytsou, Panos Ntziachristos, & Dan Starczynowski for the opportunity to speak in the session alongside @gritsmanlab.bsky.social & Marek Mraz! #ASH24 #hemesky @ash-hematology.bsky.social ash.confex.com/ash/2024/web...

Stephen Oh@mpndoc.bsky.social · 2y ago

And check out my talk on Friday afternoon at the Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies where I will be highlighting work from superstar MSTP student Tim Kong! ash.confex.com/ash/2024/web...

So sad I am missing #ASH2024 But if you’re there early enough be sure to check out the wonderful @gritsmanlab.bsky.social present exciting updates from my work at the therapy resistance workshop on Friday! 2-5pm in SDCC room 33!

Check out our new review by the amazing @alexkschurer.bsky.social and @thehematopoet.bsky.social on chromatin modifiers in AML! Just in time for the first menin inhibitor FDA approval! 🧪🩸

Shira G-S, PhD@thehematopoet.bsky.social · 2y ago

Overwhelmed by all of the exciting new research on chromatin modifiers in AML? Find it hard to keep track of all the new menin inhibitors? Well good news, we’ve just published the perfect review for you in SCTM! @alexkschurer.bsky.social @gritsmanlab.bsky.social academic.oup.com/stcltm/advan...

Women are under-represented at senior levels in #academia globally, & across all #science 🧪 disciplines, as shown by these "scissor-shaped curves" ✂️ So how can we ever achieve #gender #equality? We discuss various strategies in this #Cell Commentary #WomeninSTEM www.cell.com/cell/fulltex... 🧵 1/

Big day for our field! 🎉

First manuscript from Linde Miles Lab at CCHMC looking at clonal evolution in NPM1-mut AML at single cell resolution. Check out the pre-print here: www.biorxiv.org/content/10.1...

Genotype-immunophenotype relationships in NPM1-mutant AML clonal evolution uncovered by single cell multiomic analysis

Acute myeloid leukemia (AML) is a multi-clonal disease, existing as a milieu of clones with unique but related genotypes as initiating clones acquire subsequent mutations. However, bulk sequencing can...

biorxiv.org